Atlas Trials

A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer

Clinical trial NCT03086369 · COMPLETED

Trial details

NCT number
NCT03086369
Sponsor
Eli Lilly and Company
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Metastatic Pancreatic Cancer
Start date
2017-06-22
Primary completion
2021-01-05
Enrollment
184

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.